- Home
- AZ vs NVCT Comparison
AZ vs NVCT Comparison
Compare AZ & NVCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AZ | NVCT |
|---|---|---|
| Founded | 2018 | 2020 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.5M | 220.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AZ | NVCT |
|---|---|---|
| Price | $5.58 | $9.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $15.33 |
| AVG Volume (30 Days) | ★ 440.0K | 49.1K |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.87 | N/A |
| Revenue Next Year | $480.68 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.00 | $5.55 |
| 52 Week High | $12.36 | $11.52 |
Technical Indicators
Market Signals| Indicator | AZ | NVCT |
|---|---|---|
| Relative Strength Index (RSI) | 43.01 | 60.21 |
| Support Level | $5.10 | $8.01 |
| Resistance Level | $6.63 | $9.20 |
| Average True Range (ATR) | 0.41 | 0.42 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 41.80 | 93.20 |
Price Performance
Historical ComparisonAbout AZ A2Z Smart Technologies Corp.
A2Z Cust2Mate Solutions Corp is engaged in creating shopping carts. With the help of a user-friendly smart algorithm, touch screen, and other technologies, the company streamlines the retail shopping experience by scanning purchased products and enabling in-cart payment so that customers can simply pick & go, and bypass long cashier checkout lines.
About NVCT Nuvectis Pharma Inc.
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.